Edgar M. Moran
Professor of Medicine, Emeritus, Divison of Hematology-Oncology, Department of Medicine and the Chao Family Cancer Center
M.D., University of Bucharest School of Medicine
University of California, Irvine
Long Beach VA Healthcare System
5701 East Seventh Street
Mail Code: 8900
Long Beach, CA 90822
Long Beach VA Healthcare System
5701 East Seventh Street
Mail Code: 8900
Long Beach, CA 90822
Research Interests
Colon and Prostate Cancer; Healthcare Research: Timeliness and Effectiveness in Delivery
Academic Distinctions
Special Award for a Unique Contribution to the Mission of the Department, September 1998
Lesson of the Year Award in Primary and Ambulatory Care, Department of Veterans Affairs, February 1999
Special Award for a Unique Contribution to the Mission of the Department of Veterans Affairs, August 1999
University of California, Irvine of Medicine Academic Senate Awards, August 2002
Department of Veterans Affairs Certificate of Appreciation, July 2003
Lesson of the Year Award in Primary and Ambulatory Care, Department of Veterans Affairs, February 1999
Special Award for a Unique Contribution to the Mission of the Department of Veterans Affairs, August 1999
University of California, Irvine of Medicine Academic Senate Awards, August 2002
Department of Veterans Affairs Certificate of Appreciation, July 2003
Appointments
Associate Professor of Medicine at the University of Chicago Pritzker School of Medicine and the Franklin McLean Memorial Research Institute. (1971)
Chief, Medical Oncology, City of Hope National Medical Center, Duarte, CA (1976-1978)
Professor of Medicine, University of California, Irvine (1978-2005; Emeritus 2005 - present)
Chief of Hematology-Oncology, Long Beach VA Medical Center (1978-1992)
Chair, Cancer Program, Long Beach VA Healthcare System (1978-present)
Chief, Medical Oncology, City of Hope National Medical Center, Duarte, CA (1976-1978)
Professor of Medicine, University of California, Irvine (1978-2005; Emeritus 2005 - present)
Chief of Hematology-Oncology, Long Beach VA Medical Center (1978-1992)
Chair, Cancer Program, Long Beach VA Healthcare System (1978-present)
Research Abstract
PROFESSIONAL ABSTRACT:
Dr. Moran received his M.D. degree from the University of Bucharest School of Medicine. He trained in Pathology at the Hebrew University-Hadassah Medical School in Jerusalem, Israel, where his research centered on liver diseases and atherosclerosis. He took his internship in Internal Medicine at the University of Montreal-Hotel Dieu Hospital and his medical residency at Columbia University - Francis Delafield Hospital in New York. This was followed by a fellowship in Hematology at the Mount Sinai Medical Center in New York and in Medical Oncology at the University of Chicago.
In 1971, Dr. Moran was appointed Assistant Professor of Medicine and promoted to Associate Professor of Medicine at the University of Chicago Pritzker School of Medicine and the Franklin McLean Memorial Research Institute. His research was focused on the natural history, diagnosis, and treatment of lymphoma. In the Hematology-Oncology Section of the University of Chicago he was instrumental in establishing one of the first U.S. centers for the study of lymphomas. With colleagues in Dermatology and Radiation Oncology he also developed a national referral center for Mycosis Fungoides. In 1973, he was asked to co-direct the Program in Breast Cancer with researchers at the Ben May Laboratory for Cancer Research of the University of Chicago. In 1976, he was invited to establish the first Department of Medical Oncology at the City of Hope National Medical Center in Duarte, California.
Since 1978, he is Professor of Medicine at the University of California, Irvine and established the first academic section of Hematology-Oncology at the Long Beach Veterans Affairs Medical Center, the major academic affiliate of the University. He developed the Cancer Program of the medical center, which received its triennial approval by the Commission on Cancer. In 1997, the VA Central Office recognized this cancer program as one of the first Comprehensive Cancer Centers in the Veterans Administration.
Dr. Moran has been an active teacher of Internal Medicine, Hematology, and Medical Oncology at the University of Chicago, at the University of California, Irvine, and at the Long Beach VA Medical Center. He served many years as Chair of the UCI Curriculum and Educational Policy Committee and guided two major revisions of the preclinical curriculum of the Medical School.
Dr. Moran is a reviewer for several medical journals and served for many years as the Editor-in-Chief of the Journal of Environmental Pathology, Toxicology and Oncology, a quarterly publication.
Dr. Moran has been a visiting professor and lecturer at many academic institutions.
RESEARCH INTERESTS:
1. Lymphoma and Lymphoproliferative Diseases:
a. With the Lymphoma Group at the University of Chicago, Dr. Moran studied the natural history and clinical features and complications of Hodgkin’s disease and other lymphoma, devising and validating diagnostic methods while initiating new modalities of treatment.
b. Angio-immunoblastic Lymphadenopathy with Dysproteinemia: Dr. Moran described a novel disorder that was followed by numerous studies in many research centers. Its importance consisted in its recognition of a possible self-limited systemic immunological reaction that in some cases may evolve in a very aggressive lymphoma. The features characterizing the difference between the benign and the malignant course of this disease have been only partially documented.
c. Mycosis Fungoides: With colleagues in other disciplines Dr. Moran described the visceral and clinical evolution of this lymphoproliferative disease and introduced a modern concept in its diagnosis and treatment.
2. Natural History and Clinical Course of Solid Tumors: The factors affecting the lack of response to treatment are of particular interest. A detailed study of histopathological, radiographic, and clinical features of a malignant disorder have been conducive to novel approaches to its diagnosis and treatment. This approach led to seminal reports on the natural history of lung, head and neck, colon, and prostate cancer.
3. Environment, Cancer and Molecular Epidemiology: Starting with original observations on cancer morbidity in California, Dr. Moran expanded studied epidemiological factors that may determine the various patterns of organ involvement and cancer distribution.
Histopathological Variants of Small Cell Lung Cancer: A correlative study of histopathological variants revealed their association with different response to chemotherapy and survival.
Colon cancer location and its implications in cancer screening and detection: Observations on a large cohort of colon cancer patients revealed a changing pattern of the anatomic location of colon cancer, which has implications in cancer screening. Cancer of the proximal colon requires early detection with appropriate methodology.
Male Breast Cancer: With Dr. Hoda Anton-Culver in the Department of Epidemiology at UCI, Dr. Moran initiated a study on the “Genetic and Environmental Factors in Male Breast Cancer Risk”, that revealed new associations.
Prostate Cancer: Phenotypical differences of some patients with prostate cancer are studied.
Dr. Moran received his M.D. degree from the University of Bucharest School of Medicine. He trained in Pathology at the Hebrew University-Hadassah Medical School in Jerusalem, Israel, where his research centered on liver diseases and atherosclerosis. He took his internship in Internal Medicine at the University of Montreal-Hotel Dieu Hospital and his medical residency at Columbia University - Francis Delafield Hospital in New York. This was followed by a fellowship in Hematology at the Mount Sinai Medical Center in New York and in Medical Oncology at the University of Chicago.
In 1971, Dr. Moran was appointed Assistant Professor of Medicine and promoted to Associate Professor of Medicine at the University of Chicago Pritzker School of Medicine and the Franklin McLean Memorial Research Institute. His research was focused on the natural history, diagnosis, and treatment of lymphoma. In the Hematology-Oncology Section of the University of Chicago he was instrumental in establishing one of the first U.S. centers for the study of lymphomas. With colleagues in Dermatology and Radiation Oncology he also developed a national referral center for Mycosis Fungoides. In 1973, he was asked to co-direct the Program in Breast Cancer with researchers at the Ben May Laboratory for Cancer Research of the University of Chicago. In 1976, he was invited to establish the first Department of Medical Oncology at the City of Hope National Medical Center in Duarte, California.
Since 1978, he is Professor of Medicine at the University of California, Irvine and established the first academic section of Hematology-Oncology at the Long Beach Veterans Affairs Medical Center, the major academic affiliate of the University. He developed the Cancer Program of the medical center, which received its triennial approval by the Commission on Cancer. In 1997, the VA Central Office recognized this cancer program as one of the first Comprehensive Cancer Centers in the Veterans Administration.
Dr. Moran has been an active teacher of Internal Medicine, Hematology, and Medical Oncology at the University of Chicago, at the University of California, Irvine, and at the Long Beach VA Medical Center. He served many years as Chair of the UCI Curriculum and Educational Policy Committee and guided two major revisions of the preclinical curriculum of the Medical School.
Dr. Moran is a reviewer for several medical journals and served for many years as the Editor-in-Chief of the Journal of Environmental Pathology, Toxicology and Oncology, a quarterly publication.
Dr. Moran has been a visiting professor and lecturer at many academic institutions.
RESEARCH INTERESTS:
1. Lymphoma and Lymphoproliferative Diseases:
a. With the Lymphoma Group at the University of Chicago, Dr. Moran studied the natural history and clinical features and complications of Hodgkin’s disease and other lymphoma, devising and validating diagnostic methods while initiating new modalities of treatment.
b. Angio-immunoblastic Lymphadenopathy with Dysproteinemia: Dr. Moran described a novel disorder that was followed by numerous studies in many research centers. Its importance consisted in its recognition of a possible self-limited systemic immunological reaction that in some cases may evolve in a very aggressive lymphoma. The features characterizing the difference between the benign and the malignant course of this disease have been only partially documented.
c. Mycosis Fungoides: With colleagues in other disciplines Dr. Moran described the visceral and clinical evolution of this lymphoproliferative disease and introduced a modern concept in its diagnosis and treatment.
2. Natural History and Clinical Course of Solid Tumors: The factors affecting the lack of response to treatment are of particular interest. A detailed study of histopathological, radiographic, and clinical features of a malignant disorder have been conducive to novel approaches to its diagnosis and treatment. This approach led to seminal reports on the natural history of lung, head and neck, colon, and prostate cancer.
3. Environment, Cancer and Molecular Epidemiology: Starting with original observations on cancer morbidity in California, Dr. Moran expanded studied epidemiological factors that may determine the various patterns of organ involvement and cancer distribution.
Histopathological Variants of Small Cell Lung Cancer: A correlative study of histopathological variants revealed their association with different response to chemotherapy and survival.
Colon cancer location and its implications in cancer screening and detection: Observations on a large cohort of colon cancer patients revealed a changing pattern of the anatomic location of colon cancer, which has implications in cancer screening. Cancer of the proximal colon requires early detection with appropriate methodology.
Male Breast Cancer: With Dr. Hoda Anton-Culver in the Department of Epidemiology at UCI, Dr. Moran initiated a study on the “Genetic and Environmental Factors in Male Breast Cancer Risk”, that revealed new associations.
Prostate Cancer: Phenotypical differences of some patients with prostate cancer are studied.
Publications
SELECTED BIBLIOGRAPHY (FROM 144 PUBLISHED PAPERS):
Ultmann JE, Moran EM. Clinical course and clinical complications in Hodgkin's disease. Arch Intern Med 1973; 131:332-353.
Desser RK, Moran EM, Ultmann JE. Staging of Hodgkin's disease and lymphoma: Diagnostic procedures including staging laparotomy and splenectomy. Med Clin N Amer 1973; 57:479-498.
Ultmann JE, Moran EM. Diagnostic evaluation and clinical staging in Hodgkin's disease: Usefulness and problems of the Ann Arbor Staging Classification in primary staging and staging in relapse. Natl Cancer Inst Monogr 1973; 36:333-345.
Moran EM. Staging Classification for Non-Hodgkin's Lymphomas. In: I Linfomi Maligni. Bucalossi P, Veronesi U, Bonadonna G, Emanuelli H, eds, Casa Editrice Ambrosiana, Milan, Italy, 1974, pp. 159-166.
Moran EM, Ultmann JE. Clinical features and course of Hodgkin's disease. Clin Haematol 1974; 3:91-129.
Moran EM. The Role of Chemotherapy in the Management of Malignant Lymphomas. In: I Linfomi Maligni, Bucalossi P, Veronesi U, Bonadonna G, Emanuelli H, eds, Casa Editrice Ambrosiana, Milan, Italy, 1974, pp. 251-259.
Frizzera G, Moran EM, Rappaport H. Angio-immunoblastic lymphadenopathy with dysproteinaemia. Lancet 1974; 1:1070-1073.
Neumann H, Moran EM, Russell RM, Rosenberg IH. A distinct alkaline phosphatase found in serum of patients with lymphatic leukemia and infectious mononucleosis. Science 1974; 186:151-153.
Rappaport H, Moran EM. Angio-immunoblastic (immunoblastic) lymphadenopathy. N Engl J Med 1975; 292:42-43.
Moran EM, Ultmann JE, Ferguson DJ, Hoffer PB, Ranniger K, Rappaport H. Staging laparotomy in non-Hodgkin's lymphomas. Br J Cancer 1975; 31:228-236.
Griem ML, Moran EM, Mettler FD, Ferguson DJ, Griem SF. Staging procedures in mycosis fungoides. Br J Cancer 1975; 31:362-367.
Frizzera G, Moran EM, Rappaport H. Angio-immunoblastic lymphadenopathy. Diagnosis and clinical course. Am J Med 1975; 59:803-818.
Stein RS, Moran EM, Byrne GE Jr. Malignant histiocytosis: Complete remission with combination chemotherapy. Cancer 1976; 38:1083-1086.
Pangalis GA, Moran EM, Rappaport H. Diagnostic significance of blood and bone marrow findings in angio-immunoblastic lymphadenopathy (AILD). Blood 1977; 50:158.
Nathwani BN, Rappaport H, Moran EM, Pangalis GA, Kim H. Malignant lymphoma arising in angio-immunoblastic lymphadenopathy. Cancer 1978; 41:578-606.
Pangalis GA, Moran EM, Rappaport H. Blood and bone marrow findings in angio-immunoblastic lymphadenopathy. Blood 1978; 51:71-83.
Pangalis GA, Moran EM, Nathwani BN, Zelman RJ, Kim H, Rappaport H. Angio-immunoblastic lymphadenopathy: Long-term follow-up study. Cancer 1983; 52:318-321.
Clamon GH, Feld R, Evans WK, Weiner RS, Moran EM, Blum RH, Kramer BS, Makuch RW, Hoffman FA, DeWys WD. The effect of adjuvant central venous hyperalimentation on the survival and response to treatment of patients with small cell lung cancer: A randomized trial. Cancer Treat Rep 1985; 69:167-177.
Moran EM, Iyer PR, Kaneshiro CA. Clinical features, response to treatment and survival in small cell lung cancer (SCLC) as compared with mixed and combined histological subtypes. In: Progress in Antimicrobial and Anticancer Chemotherapy, ECOMED Publ., Landsberg/Lech, W. Germany, 1988, vol. 3, pp. 397-398.
Ultmann JE, Moran EM. Clinical course and clinical complications in Hodgkin's disease. Arch Intern Med 1973; 131:332-353.
Desser RK, Moran EM, Ultmann JE. Staging of Hodgkin's disease and lymphoma: Diagnostic procedures including staging laparotomy and splenectomy. Med Clin N Amer 1973; 57:479-498.
Ultmann JE, Moran EM. Diagnostic evaluation and clinical staging in Hodgkin's disease: Usefulness and problems of the Ann Arbor Staging Classification in primary staging and staging in relapse. Natl Cancer Inst Monogr 1973; 36:333-345.
Moran EM. Staging Classification for Non-Hodgkin's Lymphomas. In: I Linfomi Maligni. Bucalossi P, Veronesi U, Bonadonna G, Emanuelli H, eds, Casa Editrice Ambrosiana, Milan, Italy, 1974, pp. 159-166.
Moran EM, Ultmann JE. Clinical features and course of Hodgkin's disease. Clin Haematol 1974; 3:91-129.
Moran EM. The Role of Chemotherapy in the Management of Malignant Lymphomas. In: I Linfomi Maligni, Bucalossi P, Veronesi U, Bonadonna G, Emanuelli H, eds, Casa Editrice Ambrosiana, Milan, Italy, 1974, pp. 251-259.
Frizzera G, Moran EM, Rappaport H. Angio-immunoblastic lymphadenopathy with dysproteinaemia. Lancet 1974; 1:1070-1073.
Neumann H, Moran EM, Russell RM, Rosenberg IH. A distinct alkaline phosphatase found in serum of patients with lymphatic leukemia and infectious mononucleosis. Science 1974; 186:151-153.
Rappaport H, Moran EM. Angio-immunoblastic (immunoblastic) lymphadenopathy. N Engl J Med 1975; 292:42-43.
Moran EM, Ultmann JE, Ferguson DJ, Hoffer PB, Ranniger K, Rappaport H. Staging laparotomy in non-Hodgkin's lymphomas. Br J Cancer 1975; 31:228-236.
Griem ML, Moran EM, Mettler FD, Ferguson DJ, Griem SF. Staging procedures in mycosis fungoides. Br J Cancer 1975; 31:362-367.
Frizzera G, Moran EM, Rappaport H. Angio-immunoblastic lymphadenopathy. Diagnosis and clinical course. Am J Med 1975; 59:803-818.
Stein RS, Moran EM, Byrne GE Jr. Malignant histiocytosis: Complete remission with combination chemotherapy. Cancer 1976; 38:1083-1086.
Pangalis GA, Moran EM, Rappaport H. Diagnostic significance of blood and bone marrow findings in angio-immunoblastic lymphadenopathy (AILD). Blood 1977; 50:158.
Nathwani BN, Rappaport H, Moran EM, Pangalis GA, Kim H. Malignant lymphoma arising in angio-immunoblastic lymphadenopathy. Cancer 1978; 41:578-606.
Pangalis GA, Moran EM, Rappaport H. Blood and bone marrow findings in angio-immunoblastic lymphadenopathy. Blood 1978; 51:71-83.
Pangalis GA, Moran EM, Nathwani BN, Zelman RJ, Kim H, Rappaport H. Angio-immunoblastic lymphadenopathy: Long-term follow-up study. Cancer 1983; 52:318-321.
Clamon GH, Feld R, Evans WK, Weiner RS, Moran EM, Blum RH, Kramer BS, Makuch RW, Hoffman FA, DeWys WD. The effect of adjuvant central venous hyperalimentation on the survival and response to treatment of patients with small cell lung cancer: A randomized trial. Cancer Treat Rep 1985; 69:167-177.
Moran EM, Iyer PR, Kaneshiro CA. Clinical features, response to treatment and survival in small cell lung cancer (SCLC) as compared with mixed and combined histological subtypes. In: Progress in Antimicrobial and Anticancer Chemotherapy, ECOMED Publ., Landsberg/Lech, W. Germany, 1988, vol. 3, pp. 397-398.
Moran EM. Cancer in California. Prevent Med 1990; 19:596-597.
Moloy PJ; Moran EM; Azawi S. Rapid sequence treatment of advanced squamous cell carcinoma of the upper aerodigestive tract: a pilot study. Laryngoscope, 1991 Jan, 101(1 Pt 1):43-9.
Moran EM. Epidemiological factors of cancer in California. Journal of Environmental Pathology, Toxicology and Oncology, 1992 Sep-Oct, 11(5-6):303-7.
Moran EM. Environment, cancer, and molecular epidemiology: Air pollution. J
Environ Pathol Toxicol Oncol 1996; 15:97-104.
Moran EM. Environment and cancer: Air and water pollution. J Environ Pathol
Toxicol Oncol 1999; 18:234.
Moloy PJ; Moran EM; Azawi S. Rapid sequence treatment of advanced squamous cell carcinoma of the upper aerodigestive tract: a pilot study. Laryngoscope, 1991 Jan, 101(1 Pt 1):43-9.
Moran EM. Epidemiological factors of cancer in California. Journal of Environmental Pathology, Toxicology and Oncology, 1992 Sep-Oct, 11(5-6):303-7.
Moran EM. Environment, cancer, and molecular epidemiology: Air pollution. J
Environ Pathol Toxicol Oncol 1996; 15:97-104.
Moran EM. Environment and cancer: Air and water pollution. J Environ Pathol
Toxicol Oncol 1999; 18:234.
Moran EM. Epidemiological and clinical aspects of non-steroidal anti-inflammatory drugs and cancer risk. J Environ Pathol Toxicol Oncol 2002; 21:193-201.
Siston AK, Knight SJ, Slimak NP, Chmiel JS, Nadler RB, Lyons TM, Kuzel TM, Moran EM, Sharaifi R, Bennett CL. Quality of life following a diagnosis of prostate cancer inmen of lower socioeconomic status: Results from the VA Cancer of the Prostate Outcomes Study. Urology 2003; 61:172-178.
Moran, EM, Gilman, SC, Burras, RW. Colon cancer: Presentation, anatomic location, and implications in cancer screening. Hepato-Gastroenterology 2007; 54: A47.
Moran, EM, Burras, RW. Colon cancer: Significant clinical, biochemical, histopathological, and immunopathological differences between the right side (proximal) and the left side (distal) of involvement. Annals of Oncology 2010.
Siston AK, Knight SJ, Slimak NP, Chmiel JS, Nadler RB, Lyons TM, Kuzel TM, Moran EM, Sharaifi R, Bennett CL. Quality of life following a diagnosis of prostate cancer inmen of lower socioeconomic status: Results from the VA Cancer of the Prostate Outcomes Study. Urology 2003; 61:172-178.
Moran, EM, Gilman, SC, Burras, RW. Colon cancer: Presentation, anatomic location, and implications in cancer screening. Hepato-Gastroenterology 2007; 54: A47.
Moran, EM, Burras, RW. Colon cancer: Significant clinical, biochemical, histopathological, and immunopathological differences between the right side (proximal) and the left side (distal) of involvement. Annals of Oncology 2010.
Professional Societies
American Association for Cancer Research
American Society of Clinical Oncology
American Society of Preventive Oncology (Founding Member)
American Society of Hematology
International Society of Hematology (Fellow)
Society for Hematopathology
Other Experience
Editor-in-Chief, Journal of Environmental Pathology, Toxicology and Oncology
Link to this profile
https://faculty.uci.edu/profile/?facultyId=3091
https://faculty.uci.edu/profile/?facultyId=3091
Last updated
06/04/2010
06/04/2010